195 related articles for article (PubMed ID: 30635793)
1. The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice.
Alexandraki KI; Pizanias M; Uri I; Thomas D; Page T; Kolomodi D; Low CS; Adesanya O; Tsoli M; Gross DJ; Randeva H; Srirajaskanthan R; Grozinsky-Glasberg S; Kaltsas G; Weickert MO
Endocrine; 2019 Jun; 64(3):690-701. PubMed ID: 30635793
[TBL] [Abstract][Full Text] [Related]
2. Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms.
Lim KHJ; Raja H; D'Arienzo P; Barriuso J; McNamara MG; Hubner RA; Mansoor W; Valle JW; Lamarca A
Neuroendocrinology; 2020; 110(7-8):688-696. PubMed ID: 31639796
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
4. Lung Metastases in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms: An Appraisal of the Validity of Thoracic Imaging Surveillance.
Daskalakis K; Tsoli M; Srirajaskanthan R; Chatzellis E; Alexandraki K; Angelousi A; Pizanias M; Randeva H; Kaltsas G; Weickert MO
Neuroendocrinology; 2019; 108(4):308-316. PubMed ID: 30673674
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic metastases in patients with neuroendocrine neoplasms: A multi-centre cohort study.
Tsoli M; Daskalakis K; Wedin M; Angelousi A; Povlsen S; Srirajaskanthan R; Giovos G; Weickert MO; Kogut A; Kos-Kudla B; Oleinikov K; Grozinsky-Glasberg S; Kaltsas G
J Neuroendocrinol; 2023 Apr; 35(4):e13269. PubMed ID: 37102337
[TBL] [Abstract][Full Text] [Related]
6. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
10. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
11. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
12. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
13. Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications.
Merola E; Pavel ME; Panzuto F; Capurso G; Cicchese N; Rinke A; Gress TM; Iannicelli E; Prosperi D; Pizzichini P; Prasad V; Kump P; Lipp R; Partelli S; Falconi M; Wiedenmann B; Delle Fave G
J Clin Endocrinol Metab; 2017 May; 102(5):1486-1494. PubMed ID: 28324047
[TBL] [Abstract][Full Text] [Related]
14. Diffuse Bone Metastases in Pancreatic Neuroendocrine Tumor Shown on Octreoscan.
Adkins J; Lu Y
Clin Nucl Med; 2019 Mar; 44(3):257-258. PubMed ID: 30624276
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.
Panzuto F; Pusceddu S; Faggiano A; Rinzivillo M; Brighi N; Prinzi N; Riccardi F; Iannicelli E; Maggio I; Femia D; Tafuto S; Manuzzi L; Di Sarno A; Annibale B; de Braud F; Campana D;
Pancreatology; 2019 Dec; 19(8):1067-1073. PubMed ID: 31587962
[TBL] [Abstract][Full Text] [Related]
16. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis.
Garcia-Torralba E; Spada F; Lim KHJ; Jacobs T; Barriuso J; Mansoor W; McNamara MG; Hubner RA; Manoharan P; Fazio N; Valle JW; Lamarca A
Cancer Treat Rev; 2021 Mar; 94():102168. PubMed ID: 33730627
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
18. Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance.
Scharf M; Petry V; Daniel H; Rinke A; Gress TM
Neuroendocrinology; 2018; 106(1):30-37. PubMed ID: 28152537
[TBL] [Abstract][Full Text] [Related]
19. Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.
Calderone R; Nimako K; Leary A; Popat S; O'Brien ME
Eur J Cancer; 2011 Jul; 47(11):1603-5. PubMed ID: 21684152
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
